Esophageal adenocarcinoma is a cancer with rising incidence and poor survival. Most such cancers arise in a specialized intestinal metaplastic epithelium, which is diagnostic of Barrett's esophagus. In a genome-wide association study, we compared esophageal adenocarcinoma cases (n = 2,390) and individuals with precancerous Barrett's esophagus (n = 3,175) with 10,120 controls in 2 phases. For the combined case group, we identified three new associations. The first is at 19p13 (rs10419226: P = 3.6 × 10 −10 ) in CRTC1 (encoding CREB-regulated transcription coactivator), whose aberrant activation has been associated with oncogenic activity. A second is at 9q22 (rs11789015: P = 1.0 × 10 −9 ) in BARX1, which encodes a transcription factor important in esophageal specification. A third is at 3p14 (rs2687201: P = 5.5 × 10 −9 ) near the transcription factor FOXP1, which regulates esophageal development. We also refine a previously reported association with Barrett's esophagus near the putative tumor suppressor gene FOXF1 at 16q24 and extend our findings to now include esophageal adenocarcinoma.
A genetic component to the development of Barrett's esophagus and esophageal adenocarcinoma has long been suspected on the basis of previous studies in unrelated individuals and familial disease clusters [1] [2] [3] [4] [5] [6] [7] [8] [9] . The current study leverages the resources of the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON) and combines high-quality, largely population-based epidemiological studies of esophageal adenocarcinoma and Barrett's esophagus conducted over a period of two decades.
For the discovery phase, we used 1,516 esophageal adenocarcinoma cases, 2,416 Barrett's esophagus cases and 3,209 controls, all of European ancestry, after rigorous quality control procedures were applied to the genotyping data (Online Methods). The cases and 2,187 of the controls were collected by investigators in BEACON from cohort and case-control studies conducted in Western Europe, Australia and North America. An additional 1,022 cancer-free controls were obtained from a study of melanoma 10 and were included to increase statistical power. All cases were histologically confirmed. The distribution of samples by study is given in Supplementary  Table 1 , and demographic characteristics of samples are given in A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus l e t t e r s Supplementary Table 2 . All samples were genotyped on the Illumina HumanOmni1-Quad platform.
We performed association analyses on the 922,031 autosomal and X-chromosome SNPs that passed quality control using an additive logistic regression model implemented in GWASTools 11 , including as covariates age, sex and the first four eigenvectors from principalcomponent analysis (PCA). To assess variants not present on the Illumina HumanOmni1-Quad chip, we performed imputation for each region of interest (Tables 1 and 2) . To identify shared genetic susceptibility loci for the two conditions, we treated the esophageal adenocarcinoma and Barrett's esophagus cases as a representing a single phenotype. The results are shown in a Manhattan plot ( Fig. 1) . We also compared Barrett's esophagus and esophageal adenocarcinoma separately against the controls (Supplementary Fig. 1 ). Quantilequantile plots are shown in Supplementary Figure 2 . The genomic inflation factor λ for the analysis of the combined case group was 1.039 (1.084 when excluding the first four principal components); no evidence of population stratification was indicated in our data set.
We selected 94 associated (P < 1 × 10 −4 ) SNPs for replication. Of these, 87 were genotyped in 874 histologically confirmed esophageal adenocarcinoma cases from the Stomach and Oesophageal Cancer Study (SOCS), 759 were histologically confirmed Barrett's esophagus cases from the UK Barrett's Esophagus Gene Study (UK Gene Study) and 6,911 were controls, of which 1,711 were from the SEARCH Study and 5,200 were from the Wellcome Trust Case Control Consortium 2 (WTCCC2) 12 . All SOCS, UK Gene Study and SEARCH samples self-identified as Caucasian and were genotyped on a Fluidigm 96.96 Dynamic Array IFC. WTCCC2 subjects were of European ancestry, as determined by projection onto the first two principal components of a PCA of HapMap individuals, and were genotyped on a custom version of the Illumina Human1.2M-Duo array. Replication analysis was carried out using an additive logistic regression model with sex as a covariate. METAL software 13 was used for meta-analysis of the discovery and replication data sets.
The three loci that reached genome-wide significance (P < 5 × 10 −8 ) in the combined case group meta-analysis are given in Table 1 , and results for all replicated SNPs are given in Supplementary Table 3 . The most strongly associated SNP for each of the three loci had similar odds ratios (ORs) for Barrett's esophagus and esophageal adenocarcinoma. None of the top imputed SNPs showed substantially stronger association than the genotyped SNPs. npg l e t t e r s
The most significantly associated locus was found at 19p13 ( Fig. 2a ): rs10419226, P meta (BE + EA) = 3.55 × 10 −10 , OR = 1.18, 95% confidence interval (CI) = 1.12-1.24. Five imputed SNPs in high linkage disequilibrium (LD) with rs10419226 (r 2 > 0.85) had associations that reached genome-wide significance in the combined discovery data set, and two were also significant in the Barrett's esophagus discovery set ( Supplementary Table 4 ). A second significantly associated locus was identified at 9q22.32 ( Fig. 2b) : rs11789015, P meta (BE + EA) = 1.02 × 10 −9 , OR = 0.83, CI = 0.79-0.88. The third locus with genome-wide significant association was found at 3p13 (rs2687201) near FOXP1 ( Fig. 2c) : P meta (BE + EA) = 5.47 × 10 −9 , OR = 1.18, CI = 1.12-1.25.
A previous study of Barrett's esophagus identified the rs9936833 SNP, near the putative tumor suppressor gene FOXF1 (ref. 14) . A subset of the BEACON samples from the present study (2, 398 Barrett's esophagus cases and 2,167 controls) was used in the replication analysis of rs9936833 (P = 5.13 × 10 −4 , OR = 1.16, CI = 1.07-1.27). With the additional samples used here (18 Barrett's esophagus cases and 1,042 controls), the P value for association was more significant (P discovery (BE) = 1.69 × 10 −4) , but there was no change in the odds ratio (OR = 1.16, CI = 1.07-1.26). This SNP was associated with esophageal adenocarcinoma (P discovery (EA) = 2.06 × 10 −3 , OR = 1.16, CI = 1.05-1.27) ( Table 2) . Examining the regional association plot for chromosome 16 near rs9936833 for the combined data ( Fig. 2d) , we identified four nearby SNPs that had more significant P values than rs9936833. To test the independence of these associations, we fine mapped this region, using conditional analysis to assess whether the associations were due to one or multiple variants. The discovery and replication results are shown in Table 2 , with conditional analysis results shown in Table 3 . Our results indicate that these markers define a set of complex susceptibility alleles with between two and four independent loci.
The previous study of Barrett's esophagus also identified rs9257809 in the major histocompatibility complex (human leukocyte antigen, HLA) as being associated with increased risk of Barrett's esophagus 14 . The significance of association in our extended data set Shown are the discovery, replication and meta-analysis results for SNPs 100 kb up-or downstream of rs9936833, a previously identified susceptibility locus for Barrett's esophagus 14 . Data are shown for rs9936833, SNPs that had more significant P values than rs9936833 in the combined Barrett's esophagus and esophageal adenocarcinoma data set (P discovery (BE + EA) ) and SNPs that were the most significant SNP in conditional analysis in this region after fitting other SNPs (table 3) . Chr., chromosome. a Coded allele.
npg l e t t e r s (P discovery (BE) = 0.11, OR = 1.11, CI = 0.99-1.29) was not substantially different from the original replication results (P = 0.083, OR = 1.13, CI = 0.98-1.30). We found a similar OR estimate for esophageal adenocarcinoma as for Barrett's esophagus, suggesting that the previously identified genome-wide significant Barrett's esophagus association locus also has a role in esophageal adenocarcinoma risk (P discovery (EA) = 0.09, OR = 1.14, CI = 0.97-1.32; P discovery (BE + EA) = 0.06, OR = 1.12, CI = 1.01-1.27).
A previous report using BEACON data showed that Barrett's esophagus and esophageal adenocarcinoma risk is influenced by a large number of common genetic variants and that a large proportion of the genes affecting risk for these two conditions is shared between them 15 . These findings informed our choice of analysis approach, in which we primarily focused on the combined esophageal adenocarcinoma and Barrett's esophagus samples. The usefulness of this approach was borne out in the results presented here. The OR estimates after meta-analyses comparing esophageal adenocarcinoma cases versus controls and Barrett's esophagus cases versus controls for our top five loci were very similar, whereas direct comparison of the two case types showed no significant differences (data not shown). Combining the two case types allowed associations for these SNPs to clearly achieve genome-wide significance in the combined data sets ( Table 1) .
The SNPs at 19p13.11, rs10419226 and rs10423674, are intronic variants in CRTC1 (encoding CREB-regulated transcription coactivator), which is associated with oncogenic activity 16 . Phosphorylation of CRTC1 is regulated by the tumor suppressor kinase LKB1. Downregulation or loss of LKB1 expression in human esophageal cancer cell lines and patient samples resulted in activated CRTC1 signaling and the transcriptional activation of downstream targets, including STK11 (LYPD3), which is associated with cancer metastasis, leading to the promotion of esophageal cancer cell migration and invasion 16 .
rs10419226 has been shown to be an expression quantitative trait locus (eQTL) for PIK3R2 in lymphoblastoid cell lines 17 . PIK3R2 is known to be involved in cancer 18 and is expressed in gastrointestinal tumors 19 . PIK3R2 protein is also known to interact with epidermal growth factor (EGF), which has an important physiological role in the maintenance of esophageal and gastric tissue integrity. The biological effects of salivary EGF include the healing of oral and gastroesophageal ulcers and the inhibition of gastric acid secretion 20 . Furthermore, the EGF receptor has been found in gastrointestinal tissue and is expressed at higher levels in Barrett's esophagus and esophageal adenocarcinoma 21 . The homozygous G genotype for the SNP in EGF (c.61A>G variant) is associated with a two-to fourfold increase in risk for esophageal adenocarcinoma 22, 23 .
There are several SNPs in high LD (r 2 > 0.9) with rs10419226. Three of these, rs200331191, rs139340769 and rs8102046, lie in a region of probable promoter and enhancer activities across multiple cell lines 24 . The intronic CRTC1 SNP, rs10423674, influences age at menarche 25 . The basis of this pleiotropic effect is unclear but may be related to obesity, as Crtc1 −/− mice are hyperphagic and obese 26 . rs10423674 is an eQTL for PBX4 in lymphoblastoid cell lines.
The nearest gene to the peak SNP on chromosome 3 (rs2687201) is FOXP1. The transcription factors FOXP1 and FOXP2 cooperatively regulate lung and esophagus development, and FOXP1 is a therapeutic target in cancer 27, 28 . The FOX family is overexpressed in esophageal cancer 14 . There are several SNPs in high LD (r 2 > 0.8) with rs2687201 that lie within enhancer histone marks. One of these, rs7626449, is at a site where there is also evidence from DNase I hypersensitive site sequencing of transcription factor binding in esophageal epithelial cells 29 .
The rs11789015 SNP lies in an intron of BARX1, which encodes a homeobox transcription factor whose homolog is known to be involved in esophageal and trachea differentiation in developing mouse embryos and is associated with the downregulation of Wnt pathway activity in stomach morphogenesis and specification 30 . The BARX1 promoter region is hypermethylated in gastric cancer cell lines and patient samples, BARX1 mRNA expression is reduced in gastric cancer tissues and cell lines (S.J. Meltzer, personal communication). rs11789015 lies in a region where histone marks denote likely promoter activity. rs11789015 also alters a known regulatory motif for the transcription factor FOXP1. A correlated SNP, rs62574346 (r 2 = 0.97 with rs11789015), resides where there is also evidence from DNase I hypersensitive site sequencing of transcription factor binding in esophageal epithelial cells 29 .
A subset of the BEACON data presented here ( Supplementary  Fig. 3a) formed part of the replication arm of a recent Barrett's esophagus genome-wide association study (GWAS) 14 . A primary finding from that work was an association with Barrett's esophagus at 16q24 involving rs9936833. Here we found clear evidence that this locus is also associated with esophageal adenocarcinoma (P discovery (EA) = 2.06 × 10 −3 , OR = 1.16, CI = 1.05-1.27), as did a recent small study (316 esophageal adenocarcinoma cases and 602 controls; OR = 1.21, CI = 0.99-1.47) 31 . Two other SNPs near rs9936833, rs2178146 and rs3111601, have stronger and more significant associations in esophageal adenocarcinoma cases ( Table 2 and Supplementary Fig. 3b ).
Because the size and direction of the effects for the Barrett's esophagusassociated SNPs at 16q24 were similar in esophageal adenocarcinoma, we used the combined Barrett's esophagus and adenocarcinoma data to identify other SNPs that are more significantly associated at 16q24 than rs9936833 ( Table 2) . One of these was rs3111601, which was npg l e t t e r s in high LD (r 2 = 0.75) with rs9936833. All of the SNPs in high LD with rs3111601 were intergenic, although rs1979654 (r 2 = 0.64 with rs3111601) stood out as having excellent regulatory potential across a wide range of cell types and is likely to affect protein binding, chromatin structure and histone modification 29 . There was evidence for additional independent signals in the region at rs3950627 (38 kb closer to FOXF1) and rs2178146 (64 kb closer to FOXF1), as both had similar association P values to that of rs3111601 ( Fig. 2d and Table 2 Each SNP is the most significant SNP 100 kb up-or downstream of rs9936833 after fitting all SNPs in the rows above as additional covariates in the same logistic regression model used in the primary analysis. Starting with the most significant SNP in this region, rs3950627, this methodology fit four other SNPs (rows 2-5) before stopping when the P value of the most significant remaining SNP was >0.01. The last row is the P value of an association test of rs9936833 in each of these models.
npg l e t t e r s but were in only modest LD (r 2 < 0.2) with rs3111601. Neither is a good regulatory candidate, although rs8045253 (imputation association P discovery (BE + EA) = 8.04 × 10 −5 ), r 2 = 0.63 with rs3950627, changes a motif for the transcription factor FOXP1. Alteration to the way in which FOXP1 binds to this region is particularly interesting in light of our association findings on chromosome 3.
In summary, we report the first genome-wide association study of esophageal adenocarcinoma and the first to examine this cancer together with its precancerous lesion, Barrett's esophagus. Consistent with our findings showing extensive polygenic overlap between esophageal adenocarcinoma and Barrett's esophagus 15 , our most significant results were for cancer and pre-cancer combined. Together, these findings suggest that much of the genetic basis for esophageal adenocarcinoma lies in the development of Barrett's esophagus, rather than in progression from Barrett's esophagus to esophageal adenocarcinoma. We found three new genome-wide significant loci for esophageal adenocarcinoma and Barrett's esophagus combined and extended existing findings at the FOXF1 and HLA loci. One of the newly associated regions is on chromosome 3p13 near FOXP1, a gene encoding a transcription factor that regulates esophageal development. Interestingly, two of the other regions (BARX1 at 9q22.32 and FOXF1 at 16q24.1) contain risk-associated SNPs that disrupt binding of FOXP1. Further dissection of these loci is likely to lead to insights into the etiology of this rapidly fatal cancer. 
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Discovery. Study subjects. Cases of Barrett's esophagus and esophageal adenocarcinoma, together with associated population controls, were collected by investigators in the BEACON consortium. A subset of these individuals with European ancestry from epidemiological studies conducted in Western Europe, Australia and North America over the past 20 years was used in the Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS). To increase the statistical power of the study, we included additional controls from a hospital-based case-control study of melanoma 10 . These controls (MD Anderson controls) were cancer-free friends or acquaintances of European ancestry who had accompanied patients with melanoma to their clinical visits at the MD Anderson Cancer Center in Houston, Texas. The distribution of samples by study is given in Supplementary Table 1 .
Histological confirmation of esophageal adenocarcinoma was carried out for all esophageal adenocarcinoma studies. Similarly, Barrett's esophagus was histologically confirmed via identification of goblet cells in metaplastic columnar epithelium in a biopsy taken from the esophagus. Age, sex ( Supplementary  Table 2 ) and other esophageal adenocarcinoma/Barrett's esophagus risk factors were collected by all of the included studies via standardized questionnaires, usually through personal interviews. All recruited participants gave informed consent, and this project was approved by the ethics boards of each participating institution.
Genotyping. BEAGESS specimens were shipped to the Fred Hutchinson Cancer Research Center (Seattle, Washington) where they were processed and genotyped in three batches. In each batch, samples on each genotyping plate were stratified and balanced according to case-control status, study and sex, with samples assigned to plates randomly within these strata. Genotyping of DNA from buffy coat or whole blood was performed using the Illumina HumanOmni1-Quad platform. MD Anderson controls were genotyped using the Illumina HumanOmni1-Quad platform at the Johns Hopkins University Center for Inherited Disease Research (CIDR). SNP annotations were based on version H of the Illumina product files and corresponded to the Genome Reference Consortium GRCh37 release.
Quality control. Quality assurance and quality control for the BEAGESS and MD Anderson data sets were carried out independently by the Genetics Coordinating Center at the University of Washington following standard procedures 32 . Quality assurance and quality control for the MD Anderson data set was described previously 10 . BEAGESS samples with call rate < 95%, admixture of more than one DNA source or unexpected relatedness (including unexpected duplicates) or misannotated sex that could not be explained were removed from the data set. We looked for batch and plate effects using intensity data and allelic frequency and checked for case-control associations with different experimental factors. No important batch or plate effects or case-control associations with experimental factors were found. We used heterozygosity, sex chromosome intensity data, identity-by-descent (IBD) analysis and visualization of B allele frequency (BAF) and log R ratio (LRR) plots to identify samples that had one or more of misannotated sex, unexpected relatedness or were sample mixtures 33 . Two additional sample mixtures were removed from the data set. After further sample filtering to retain only unrelated samples with European ancestry (see next section), 2,416 Barrett's esophagus cases, 1,516 esophageal adenocarcinoma cases and 2,187 controls remained. These samples were combined with 1,022 controls of European ancestry from the MD Anderson data set for discovery analysis.
SNPs were clustered using Illumina's GenomeStudio software, and SNP clusters were defined using all samples with call rate >95%. SNPs that had either GenTrain score <0.6 or cluster separation value <0.4 had their genotypes set to missing. Additionally, we filtered out SNPs that were intensity only, had missing call rate >5%, had Hardy-Weinberg equilibrium P value over controls ≥10 −4 , had one or more discordances among any of the duplicate pairs or had a mendelian error in either BEAGESS families or HapMap trios. These filters were combined, with similar filters calculated for the MD Anderson data set 10 . Additionally, we removed a further 344 SNPs that were discordant in the same HapMap control samples (n = 3) run in both the BEAGESS and MD Anderson data sets. After quality assurance and quality control, a total of 926,923 SNPs remained for analysis.
PCA. We performed PCA as a two-step process using SNPRelate software. First, we used PCA to define a homogeneous set of samples with European ancestry in the BEAGESS data set. We did this by running PCA on a set of 6,248 unrelated subjects (with the exception of six two-person families) each of whom was an esophageal adenocarcinoma case, a Barrett's esophagus case or a control. A majority of these subjects (~98%) self-identified as 'white' , and a scatter plot of all subjects along the axes of the first two eigenvectors showed that the majority of samples formed a tight cluster (Supplementary Fig. 4) . Therefore, we computed the means and standard deviations of the first two eigenvectors and defined any sample that fell within a 2-s.d. rectangle of both eigenvector means to be of homogeneous European ancestry (n = 6,125).
Second, we ran PCA on the combined data set (n = 7,147) consisting of the BEAGESS samples of European ancestry (n = 6,125) and the similarly defined set of MD Anderson controls (n = 1,022). The intent was to identify eigenvectors to include as covariates in our model to adjust for population differences that were present in the remaining European-ancestry-only samples 34, 35 . For this analysis, we selected 65,774 SNPs that were nonmonomorphic, autosomal, passed quality control, had missing call rate <5%, had minor allele frequency >5%, did not have LD value >0.2 between any two SNPs in a sliding window of 500,000 bases and were not in the LCT gene (2q21), HLA region or polymorphic regions on chromosomes 8 (8p23) and 17 (17q21.31) . We included the first four eigenvectors as covariates in the association test model to account for population stratification by ancestry because they were significantly correlated with case-control status, and a scree plot showed that the variance accounted for by each eigenvector flattened out after these four eigenvectors were included (data not shown). To check that only genome-wide variation was detected, we computed the absolute value of the correlation coefficient of each eigenvector against the genotypes for each SNP. We observed one small region of high correlation (ρ = ~0.4) between the first eigenvector and chromosome 2, which may indicate long-range LD with the LCT gene.
Statistical analysis. After excluding six related samples and six other samples that had missing call rate >2%, we ran a case-control analysis of the remaining 7,135 samples: 3,928 cases (1,514 esophageal adenocarcinoma and 2,414 Barrett's esophagus) versus 3,207 controls. We used an additive logistic regression model with case status regressed on each SNP's genotype score (coded as 0, 1 or 2 for BB, AB and AA, respectively), including as covariates age, sex and the first four PCA eigenvectors, to compute the OR and 95% CI values relating risk of esophageal adenocarcinoma or Barrett's esophagus to a given SNP variant. To test SNPs on the X chromosome, male genotypes were coded as 0 and 2, and female genotypes were coded as 0, 1 and 2. After filtering out SNPs that did not pass quality control and SNPs with minor allele frequency <1%, the λ value was 1.04. The quantile-quantile plot is shown in Supplementary Figure 2 . We also compared Barrett's esophagus and esophageal adenocarcinoma cases separately against the controls using the same model. The corresponding Manhattan and quantile-quantile plots are shown in Supplementary Figures 1 and 2, respectively. Analysis was carried out in the R statistical programming language 36 using the Bioconductor packages GWASTools 11 and SNPRelate 37 .
Using the combined Barrett's esophagus and esophageal adenocarcinoma discovery data set, we performed a stepwise series of nested logistic regression analyses to test the independence of the associations at 16q24 near rs9936833. We used the same logistic regression model and covariates as in our primary analysis and also fitted rs3950627 as a covariate because it was the most significant SNP 100 kb up-or downstream of rs9936833. This conditional analysis identified rs2178146 as the most significant SNP 100 kb up-or downstream of rs9936833. We repeated this analysis four more times, identifying and adding to each successive model rs2178146, rs3111601, rs1490865 and rs13332095, respectively, stopping when the P value of the most significant remaining SNP was >0.01 ( Table 3) .
Imputation. To assess the impact of variants not present on the Illumina HumanOmni1-Quad chip, we imputed genotypes using MaCH 38 software and a European reference panel from the 1000 Genomes project. At each region in Tables 1 and 2, imputation was carried out in two steps. First, haplotypes were estimated in a prephasing step. Second, missing alleles for additional SNPs were imputed onto these phased haplotypes using Minimac 38 and a publicly available reference panel of haplotypes from populations of European ancestry. SNPs with very different allele frequencies (χ 2 statistic > 40 in a test for difference in allele frequency) in the BEACON data and the reference panel npg were removed before the second step. SNPs with MACH imputation r 2 < 0.3 (a measure of imputation quality) and SNPs with minor allele frequency <1% were also removed. Association analysis between imputed SNPs and disease status was performed using the same regression model as for genotyped SNPs but with dosage probabilities as predictors instead of the actual genotype calls. All association tests were two-sided. LD calculations (r 2 ) were performed with the discovery data when the two SNPs being compared were both genotyped; otherwise, samples of European ancestry from Phase 1 of the 1000 Genomes Project were used.
Replication. SNP selection. We selected SNPs after quality assurance and quality control for replication that had P value from discovery <1 × 10 −4 and minor allele frequency >1%. This yielded 406 SNPs: 179 from Barrett's esophagus and esophageal adenocarcinoma versus controls, 105 from esophageal adenocarcinoma versus controls and 122 from Barrett's esophagus versus controls; 321 were unique. A subset of these SNPs (n = 111) was selected via LD pruning with PLINK using the command clump 39 ; if a SNP had LD > 0.5 with any other SNP(s) in the list, the SNP with the lowest P value was selected for replication. For each of the ten SNPs on this list with the smallest P value, we selected an additional 'proxy' SNP to include in case the top SNP was not successfully genotyped in the replication set. These proxy SNPs were in high LD with the top SNP but had less significant P values. We visually examined cluster plots of all SNPs and kept only those that were high quality. SNPs were rank ordered by P value, and replication was attempted for the top 94.
Study subjects. The replication cohort consisted of Barrett's esophagus cases, esophageal adenocarcinoma cases and two control sets. Barrett's esophagus cases were identified at endoscopy with a confirmed histopathological diagnosis of intestinal metaplasia from the UK Barrett's Esophagus Gene Study. Esophageal adenocarcinoma cases were selected from SOCS and had an International Classification of Diseases coding of malignant neoplasm of the esophagus (C15) and a pathological diagnosis of adenocarcinoma. One set of controls came from the SEARCH study, which ascertains eligible cases of breast, ovarian, prostate, colorectal, melanoma and endometrial cancer from the UK Eastern Cancer Registration and Information Centre. Controls were ascertained by frequency matching on the basis of age (5-year age bands) and sex to the esophageal adenocarcinoma and Barrett's esophagus cases, excluding individuals with a past history of cancer (excluding non-melanoma skin cancer). All recruited participants gave informed consent, and the studies have been approved by the relevant institutional ethics review board. The other set of controls was from WTCCC2.
Genotyping. Barrett's esophagus cases, esophageal adenocarcinoma cases and SEARCH controls were genotyped using the Fluidigm high-throughput platform and Fluidigm 96.96 Dynamic Arrays according to the manufacturer's instructions and were read using the Fluidigm EP1. Each array is capable of running 96 samples against 96 SNP assays. Cases and controls were plated in sets of 96 samples and combined into 384-well arrays for genotyping, with the cases and controls mixed on each 384-well plate. Genotypes were automatically called using BioMark Genotyping Analysis software, but all cluster plots were also checked manually and adjusted as needed. The WTCCC2 controls were genotyped on a custom version of the Illumina Human1.2M-Duo array.
Quality control. We filtered out Barrett's esophagus cases, esophageal adenocarcinoma cases and SEARCH controls that had low call rate, had inconsistent sex, were duplicates or had self-reported ancestry of 'non-white' or 'missing' . This left 759 Barrett's esophagus cases, 874 esophageal adenocarcinoma cases and 1,711 SEARCH controls. We excluded SNPs with missing call rate ≥5%, with significant differential missing call rates in cases and controls (P < 5 × 10 −4 ), with low minor allele frequency (defined as <1%), and with significant departure from Hardy-Weinberg equilibrium (P < 0.0005), retaining 87 SNPs after quality control. We applied standard sample and SNP exclusion criteria to the WTCCC2 controls, retaining 5,190 samples of European ancestry after quality control. There were 67 SNPs after quality control in the WTCCC2 controls in common with the 87 SNPs after quality control in the Barrett's esophagus cases, esophageal adenocarcinoma cases and SEARCH controls.
Statistical analysis. Each of the 87 SNPs was run using an additive logistic regression model with case status regressed on SNP genotype and including sex as a covariate. The analysis focus was on the comparison of Barrett's esophagus and esophageal adenocarcinoma cases against controls, but we also ran each case type separately against the controls. The final data set used for replication consisted of 759 Barrett's esophagus cases and 874 esophageal adenocarcinoma cases. For 67 SNPs, the control set consisted of 6,911 samples: 1,711 SEARCH controls and 5,200 WTCCC2 controls. For 20 SNPs that were not genotyped in the WTCCC2 data, only the 1,711 SEARCH controls were used. The R statistical programming language was used for all analyses.
Meta-analysis.
We used the inverse variance-based method in METAL software 13 to perform a meta-analysis of the discovery and replication data sets. This approach weights the effect size estimates (β coefficients from the discovery and replication regression models) by their standard error estimates and calculates an overall z score and P value. This analysis was carried out separately for each sample set.
Bioinformatics and functional genomics. Each region of interest was interrogated using the tools eQTL browser, HaploReg, RegulomeDB and the UCSC Genome Browser.
